http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 02 Jun 2026 17:20:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++NKGen+Biotech%2C+Inc.+++++++For%3A+May+27/26593274.html si-local-file:///var/storage/secattach/20260602/26593274.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++NKGen+Biotech%2C+Inc.+++++++For%3A+May+27/26593274.html Tue, 02 Jun 2026 17:20:00 -0400 NKGN O.50689666 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++NKGen+Biotech%2C+Inc.+++++++For%3A+May+27/26593274.html si-local-file:///var/storage/secattach/20260602/26593274.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++NKGen+Biotech%2C+Inc.+++++++For%3A+May+27/26593274.html Tue, 02 Jun 2026 17:20:00 -0400 NKGN O.50689666 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++NKGen+Biotech%2C+Inc.+++++++For%3A+May+15/26536907.html si-local-file:///var/storage/secattach/20260521/26536907.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++NKGen+Biotech%2C+Inc.+++++++For%3A+May+15/26536907.html Thu, 21 May 2026 17:20:00 -0400 NKGN O.50689666 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++NKGen+Biotech%2C+Inc.+++++++For%3A+May+15/26536907.html si-local-file:///var/storage/secattach/20260521/26536907.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++NKGen+Biotech%2C+Inc.+++++++For%3A+May+15/26536907.html Thu, 21 May 2026 17:20:00 -0400 NKGN O.50689666 http://www.streetinsider.com/Press+Releases/NKGen+Biotech+Expands+Clinical+Trial+Site+Network+for+Alzheimer%E2%80%99s+Disease+Program+Across+U.S.+to+Improve+Patient+Access+and+Support+Enrollment/26517698.html <p><em>New sites in New Jersey, New York, and Florida broaden geographic reach and increase access for patients participating in Phase 2 trial of troculeucel in moderate Alzheimer’s disease.</em></p> <p align="justify">SANTA ANA, Calif., May 19, 2026 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer (“NK”) cell therapeutics, today announced the activation of three additional clinical trial sites in the United States for its ongoing Phase 2 study of troculeucel in moderate Alzheimer’s disease.</p> <p align="justify">The new http://www.streetinsider.com/Press+Releases/NKGen+Biotech+Expands+Clinical+Trial+Site+Network+for+Alzheimer%E2%80%99s+Disease+Program+Across+U.S.+to+Improve+Patient+Access+and+Support+Enrollment/26517698.html Tue, 19 May 2026 08:05:00 -0400 A.17568957 A.50216777 NKGN O.04889877 O.50689666 O.54516537 http://www.streetinsider.com/Press+Releases/NKGen+Biotech+Expands+Clinical+Trial+Site+Network+for+Alzheimer%E2%80%99s+Disease+Program+Across+U.S.+to+Improve+Patient+Access+and+Support+Enrollment/26517698.html <p><em>New sites in New Jersey, New York, and Florida broaden geographic reach and increase access for patients participating in Phase 2 trial of troculeucel in moderate Alzheimer’s disease.</em></p> <p align="justify">SANTA ANA, Calif., May 19, 2026 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer (“NK”) cell therapeutics, today announced the activation of three additional clinical trial sites in the United States for its ongoing Phase 2 study of troculeucel in moderate Alzheimer’s disease.</p> <p align="justify">The new http://www.streetinsider.com/Press+Releases/NKGen+Biotech+Expands+Clinical+Trial+Site+Network+for+Alzheimer%E2%80%99s+Disease+Program+Across+U.S.+to+Improve+Patient+Access+and+Support+Enrollment/26517698.html Tue, 19 May 2026 08:05:00 -0400 A.17568957 A.50216777 NKGN O.04889877 O.50689666 O.54516537 http://www.streetinsider.com/Press+Releases/NKGen+Biotech+Expands+Clinical+Trial+Site+Network+for+Alzheimer%E2%80%99s+Disease+Program+Across+U.S.+to+Improve+Patient+Access+and+Support+Enrollment/26517698.html <p><em>New sites in New Jersey, New York, and Florida broaden geographic reach and increase access for patients participating in Phase 2 trial of troculeucel in moderate Alzheimer’s disease.</em></p> <p align="justify">SANTA ANA, Calif., May 19, 2026 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer (“NK”) cell therapeutics, today announced the activation of three additional clinical trial sites in the United States for its ongoing Phase 2 study of troculeucel in moderate Alzheimer’s disease.</p> <p align="justify">The new http://www.streetinsider.com/Press+Releases/NKGen+Biotech+Expands+Clinical+Trial+Site+Network+for+Alzheimer%E2%80%99s+Disease+Program+Across+U.S.+to+Improve+Patient+Access+and+Support+Enrollment/26517698.html Tue, 19 May 2026 08:05:00 -0400 A.17568957 A.50216777 NKGN O.04889877 O.50689666 O.54516537 http://www.streetinsider.com/Press+Releases/NKGen+Biotech+Expands+Clinical+Trial+Site+Network+for+Alzheimer%E2%80%99s+Disease+Program+Across+U.S.+to+Improve+Patient+Access+and+Support+Enrollment/26517698.html <p><em>New sites in New Jersey, New York, and Florida broaden geographic reach and increase access for patients participating in Phase 2 trial of troculeucel in moderate Alzheimer’s disease.</em></p> <p align="justify">SANTA ANA, Calif., May 19, 2026 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer (“NK”) cell therapeutics, today announced the activation of three additional clinical trial sites in the United States for its ongoing Phase 2 study of troculeucel in moderate Alzheimer’s disease.</p> <p align="justify">The new http://www.streetinsider.com/Press+Releases/NKGen+Biotech+Expands+Clinical+Trial+Site+Network+for+Alzheimer%E2%80%99s+Disease+Program+Across+U.S.+to+Improve+Patient+Access+and+Support+Enrollment/26517698.html Tue, 19 May 2026 08:05:00 -0400 A.17568957 A.50216777 NKGN O.04889877 O.50689666 O.54516537 http://www.streetinsider.com/Press+Releases/NKGen+Biotech+Expands+Clinical+Trial+Site+Network+for+Alzheimer%E2%80%99s+Disease+Program+Across+U.S.+to+Improve+Patient+Access+and+Support+Enrollment/26517698.html <p><em>New sites in New Jersey, New York, and Florida broaden geographic reach and increase access for patients participating in Phase 2 trial of troculeucel in moderate Alzheimer’s disease.</em></p> <p align="justify">SANTA ANA, Calif., May 19, 2026 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer (“NK”) cell therapeutics, today announced the activation of three additional clinical trial sites in the United States for its ongoing Phase 2 study of troculeucel in moderate Alzheimer’s disease.</p> <p align="justify">The new http://www.streetinsider.com/Press+Releases/NKGen+Biotech+Expands+Clinical+Trial+Site+Network+for+Alzheimer%E2%80%99s+Disease+Program+Across+U.S.+to+Improve+Patient+Access+and+Support+Enrollment/26517698.html Tue, 19 May 2026 08:05:00 -0400 A.17568957 A.50216777 NKGN O.04889877 O.50689666 O.54516537 http://www.streetinsider.com/Press+Releases/NKGen+Biotech+Expands+Clinical+Trial+Site+Network+for+Alzheimer%E2%80%99s+Disease+Program+Across+U.S.+to+Improve+Patient+Access+and+Support+Enrollment/26517698.html <p><em>New sites in New Jersey, New York, and Florida broaden geographic reach and increase access for patients participating in Phase 2 trial of troculeucel in moderate Alzheimer’s disease.</em></p> <p align="justify">SANTA ANA, Calif., May 19, 2026 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer (“NK”) cell therapeutics, today announced the activation of three additional clinical trial sites in the United States for its ongoing Phase 2 study of troculeucel in moderate Alzheimer’s disease.</p> <p align="justify">The new http://www.streetinsider.com/Press+Releases/NKGen+Biotech+Expands+Clinical+Trial+Site+Network+for+Alzheimer%E2%80%99s+Disease+Program+Across+U.S.+to+Improve+Patient+Access+and+Support+Enrollment/26517698.html Tue, 19 May 2026 08:05:00 -0400 A.17568957 A.50216777 NKGN O.04889877 O.50689666 O.54516537 http://www.streetinsider.com/Globe+Newswire/NKGen+Biotech+Expands+Clinical+Trial+Site+Network+for+Alzheimer%E2%80%99s+Disease+Program+Across+U.S.+to+Improve+Patient+Access+and+Support+Enrollment/26517698.html <p><em>New sites in New Jersey, New York, and Florida broaden geographic reach and increase access for patients participating in Phase 2 trial of troculeucel in moderate Alzheimer’s disease.</em></p> <p align="justify">SANTA ANA, Calif., May 19, 2026 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer (“NK”) cell therapeutics, today announced the activation of three additional clinical trial sites in the United States for its ongoing Phase 2 study of troculeucel in moderate Alzheimer’s disease.</p> <p align="justify">The new http://www.streetinsider.com/Globe+Newswire/NKGen+Biotech+Expands+Clinical+Trial+Site+Network+for+Alzheimer%E2%80%99s+Disease+Program+Across+U.S.+to+Improve+Patient+Access+and+Support+Enrollment/26517698.html Tue, 19 May 2026 08:05:00 -0400 A.17568957 A.50216777 NKGN O.04889877 O.50689666 O.54516537 http://www.streetinsider.com/Globe+Newswire/NKGen+Biotech+Expands+Clinical+Trial+Site+Network+for+Alzheimer%E2%80%99s+Disease+Program+Across+U.S.+to+Improve+Patient+Access+and+Support+Enrollment/26517698.html <p><em>New sites in New Jersey, New York, and Florida broaden geographic reach and increase access for patients participating in Phase 2 trial of troculeucel in moderate Alzheimer’s disease.</em></p> <p align="justify">SANTA ANA, Calif., May 19, 2026 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer (“NK”) cell therapeutics, today announced the activation of three additional clinical trial sites in the United States for its ongoing Phase 2 study of troculeucel in moderate Alzheimer’s disease.</p> <p align="justify">The new http://www.streetinsider.com/Globe+Newswire/NKGen+Biotech+Expands+Clinical+Trial+Site+Network+for+Alzheimer%E2%80%99s+Disease+Program+Across+U.S.+to+Improve+Patient+Access+and+Support+Enrollment/26517698.html Tue, 19 May 2026 08:05:00 -0400 A.17568957 A.50216777 NKGN O.04889877 O.50689666 O.54516537 http://www.streetinsider.com/Globe+Newswire/NKGen+Biotech+Expands+Clinical+Trial+Site+Network+for+Alzheimer%E2%80%99s+Disease+Program+Across+U.S.+to+Improve+Patient+Access+and+Support+Enrollment/26517698.html <p><em>New sites in New Jersey, New York, and Florida broaden geographic reach and increase access for patients participating in Phase 2 trial of troculeucel in moderate Alzheimer’s disease.</em></p> <p align="justify">SANTA ANA, Calif., May 19, 2026 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer (“NK”) cell therapeutics, today announced the activation of three additional clinical trial sites in the United States for its ongoing Phase 2 study of troculeucel in moderate Alzheimer’s disease.</p> <p align="justify">The new http://www.streetinsider.com/Globe+Newswire/NKGen+Biotech+Expands+Clinical+Trial+Site+Network+for+Alzheimer%E2%80%99s+Disease+Program+Across+U.S.+to+Improve+Patient+Access+and+Support+Enrollment/26517698.html Tue, 19 May 2026 08:05:00 -0400 A.17568957 A.50216777 NKGN O.04889877 O.50689666 O.54516537 http://www.streetinsider.com/Globe+Newswire/NKGen+Biotech+Expands+Clinical+Trial+Site+Network+for+Alzheimer%E2%80%99s+Disease+Program+Across+U.S.+to+Improve+Patient+Access+and+Support+Enrollment/26517698.html <p><em>New sites in New Jersey, New York, and Florida broaden geographic reach and increase access for patients participating in Phase 2 trial of troculeucel in moderate Alzheimer’s disease.</em></p> <p align="justify">SANTA ANA, Calif., May 19, 2026 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer (“NK”) cell therapeutics, today announced the activation of three additional clinical trial sites in the United States for its ongoing Phase 2 study of troculeucel in moderate Alzheimer’s disease.</p> <p align="justify">The new http://www.streetinsider.com/Globe+Newswire/NKGen+Biotech+Expands+Clinical+Trial+Site+Network+for+Alzheimer%E2%80%99s+Disease+Program+Across+U.S.+to+Improve+Patient+Access+and+Support+Enrollment/26517698.html Tue, 19 May 2026 08:05:00 -0400 A.17568957 A.50216777 NKGN O.04889877 O.50689666 O.54516537 http://www.streetinsider.com/Globe+Newswire/NKGen+Biotech+Expands+Clinical+Trial+Site+Network+for+Alzheimer%E2%80%99s+Disease+Program+Across+U.S.+to+Improve+Patient+Access+and+Support+Enrollment/26517698.html <p><em>New sites in New Jersey, New York, and Florida broaden geographic reach and increase access for patients participating in Phase 2 trial of troculeucel in moderate Alzheimer’s disease.</em></p> <p align="justify">SANTA ANA, Calif., May 19, 2026 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer (“NK”) cell therapeutics, today announced the activation of three additional clinical trial sites in the United States for its ongoing Phase 2 study of troculeucel in moderate Alzheimer’s disease.</p> <p align="justify">The new http://www.streetinsider.com/Globe+Newswire/NKGen+Biotech+Expands+Clinical+Trial+Site+Network+for+Alzheimer%E2%80%99s+Disease+Program+Across+U.S.+to+Improve+Patient+Access+and+Support+Enrollment/26517698.html Tue, 19 May 2026 08:05:00 -0400 A.17568957 A.50216777 NKGN O.04889877 O.50689666 O.54516537 http://www.streetinsider.com/Globe+Newswire/NKGen+Biotech+Expands+Clinical+Trial+Site+Network+for+Alzheimer%E2%80%99s+Disease+Program+Across+U.S.+to+Improve+Patient+Access+and+Support+Enrollment/26517698.html <p><em>New sites in New Jersey, New York, and Florida broaden geographic reach and increase access for patients participating in Phase 2 trial of troculeucel in moderate Alzheimer’s disease.</em></p> <p align="justify">SANTA ANA, Calif., May 19, 2026 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer (“NK”) cell therapeutics, today announced the activation of three additional clinical trial sites in the United States for its ongoing Phase 2 study of troculeucel in moderate Alzheimer’s disease.</p> <p align="justify">The new http://www.streetinsider.com/Globe+Newswire/NKGen+Biotech+Expands+Clinical+Trial+Site+Network+for+Alzheimer%E2%80%99s+Disease+Program+Across+U.S.+to+Improve+Patient+Access+and+Support+Enrollment/26517698.html Tue, 19 May 2026 08:05:00 -0400 A.17568957 A.50216777 NKGN O.04889877 O.50689666 O.54516537 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++NKGen+Biotech%2C+Inc.+++++++For%3A+Apr+28/26427382.html si-local-file:///var/storage/secattach/20260504/26427382.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++NKGen+Biotech%2C+Inc.+++++++For%3A+Apr+28/26427382.html Mon, 04 May 2026 17:25:00 -0400 NKGN O.50689666 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++NKGen+Biotech%2C+Inc.+++++++For%3A+Apr+28/26427382.html si-local-file:///var/storage/secattach/20260504/26427382.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++NKGen+Biotech%2C+Inc.+++++++For%3A+Apr+28/26427382.html Mon, 04 May 2026 17:25:00 -0400 NKGN O.50689666 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++NKGen+Biotech%2C+Inc.+++++++For%3A+Apr+15/26345395.html si-local-file:///var/storage/secattach/20260421/26345395.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++NKGen+Biotech%2C+Inc.+++++++For%3A+Apr+15/26345395.html Tue, 21 Apr 2026 17:20:00 -0400 NKGN O.50689666 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++NKGen+Biotech%2C+Inc.+++++++For%3A+Apr+15/26345395.html si-local-file:///var/storage/secattach/20260421/26345395.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++NKGen+Biotech%2C+Inc.+++++++For%3A+Apr+15/26345395.html Tue, 21 Apr 2026 17:20:00 -0400 NKGN O.50689666 http://www.streetinsider.com/Press+Releases/NKGen+Biotech+to+Present+Troculeucel+Mechanism+Data+in+Alzheimer%E2%80%99s+and+Frontotemporal+Dementia+at+the+Neuroimmunology+Drug+Development+Summit/26292523.html <p align="justify">SANTA ANA, Calif., April 09, 2026 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer (“NK”) cell therapeutics, today announced that it will present data on its lead investigational program, troculeucel, at the 8th Annual Neuroimmunology Drug Development Summit being held April 14-16, 2026, in Boston, Massachusetts.</p> <p align="justify">NKGen’s Chairman and Chief Executive Officer, Dr. Paul Y. Song, M.D., will highlight the therapeutic rationale supporting troculeucel’s use in neurodegenerative diseases, including Alzheimer’s disease and frontotemporal dementia http://www.streetinsider.com/Press+Releases/NKGen+Biotech+to+Present+Troculeucel+Mechanism+Data+in+Alzheimer%E2%80%99s+and+Frontotemporal+Dementia+at+the+Neuroimmunology+Drug+Development+Summit/26292523.html Thu, 09 Apr 2026 08:05:00 -0400 A.17568957 A.50216539 NKGN O.01981133 O.04889877 O.50689666 http://www.streetinsider.com/Press+Releases/NKGen+Biotech+to+Present+Troculeucel+Mechanism+Data+in+Alzheimer%E2%80%99s+and+Frontotemporal+Dementia+at+the+Neuroimmunology+Drug+Development+Summit/26292523.html <p align="justify">SANTA ANA, Calif., April 09, 2026 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer (“NK”) cell therapeutics, today announced that it will present data on its lead investigational program, troculeucel, at the 8th Annual Neuroimmunology Drug Development Summit being held April 14-16, 2026, in Boston, Massachusetts.</p> <p align="justify">NKGen’s Chairman and Chief Executive Officer, Dr. Paul Y. Song, M.D., will highlight the therapeutic rationale supporting troculeucel’s use in neurodegenerative diseases, including Alzheimer’s disease and frontotemporal dementia http://www.streetinsider.com/Press+Releases/NKGen+Biotech+to+Present+Troculeucel+Mechanism+Data+in+Alzheimer%E2%80%99s+and+Frontotemporal+Dementia+at+the+Neuroimmunology+Drug+Development+Summit/26292523.html Thu, 09 Apr 2026 08:05:00 -0400 A.17568957 A.50216539 NKGN O.01981133 O.04889877 O.50689666 http://www.streetinsider.com/Press+Releases/NKGen+Biotech+to+Present+Troculeucel+Mechanism+Data+in+Alzheimer%E2%80%99s+and+Frontotemporal+Dementia+at+the+Neuroimmunology+Drug+Development+Summit/26292523.html <p align="justify">SANTA ANA, Calif., April 09, 2026 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer (“NK”) cell therapeutics, today announced that it will present data on its lead investigational program, troculeucel, at the 8th Annual Neuroimmunology Drug Development Summit being held April 14-16, 2026, in Boston, Massachusetts.</p> <p align="justify">NKGen’s Chairman and Chief Executive Officer, Dr. Paul Y. Song, M.D., will highlight the therapeutic rationale supporting troculeucel’s use in neurodegenerative diseases, including Alzheimer’s disease and frontotemporal dementia http://www.streetinsider.com/Press+Releases/NKGen+Biotech+to+Present+Troculeucel+Mechanism+Data+in+Alzheimer%E2%80%99s+and+Frontotemporal+Dementia+at+the+Neuroimmunology+Drug+Development+Summit/26292523.html Thu, 09 Apr 2026 08:05:00 -0400 A.17568957 A.50216539 NKGN O.01981133 O.04889877 O.50689666 http://www.streetinsider.com/Press+Releases/NKGen+Biotech+to+Present+Troculeucel+Mechanism+Data+in+Alzheimer%E2%80%99s+and+Frontotemporal+Dementia+at+the+Neuroimmunology+Drug+Development+Summit/26292523.html <p align="justify">SANTA ANA, Calif., April 09, 2026 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer (“NK”) cell therapeutics, today announced that it will present data on its lead investigational program, troculeucel, at the 8th Annual Neuroimmunology Drug Development Summit being held April 14-16, 2026, in Boston, Massachusetts.</p> <p align="justify">NKGen’s Chairman and Chief Executive Officer, Dr. Paul Y. Song, M.D., will highlight the therapeutic rationale supporting troculeucel’s use in neurodegenerative diseases, including Alzheimer’s disease and frontotemporal dementia http://www.streetinsider.com/Press+Releases/NKGen+Biotech+to+Present+Troculeucel+Mechanism+Data+in+Alzheimer%E2%80%99s+and+Frontotemporal+Dementia+at+the+Neuroimmunology+Drug+Development+Summit/26292523.html Thu, 09 Apr 2026 08:05:00 -0400 A.17568957 A.50216539 NKGN O.01981133 O.04889877 O.50689666 http://www.streetinsider.com/Press+Releases/NKGen+Biotech+to+Present+Troculeucel+Mechanism+Data+in+Alzheimer%E2%80%99s+and+Frontotemporal+Dementia+at+the+Neuroimmunology+Drug+Development+Summit/26292523.html <p align="justify">SANTA ANA, Calif., April 09, 2026 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer (“NK”) cell therapeutics, today announced that it will present data on its lead investigational program, troculeucel, at the 8th Annual Neuroimmunology Drug Development Summit being held April 14-16, 2026, in Boston, Massachusetts.</p> <p align="justify">NKGen’s Chairman and Chief Executive Officer, Dr. Paul Y. Song, M.D., will highlight the therapeutic rationale supporting troculeucel’s use in neurodegenerative diseases, including Alzheimer’s disease and frontotemporal dementia http://www.streetinsider.com/Press+Releases/NKGen+Biotech+to+Present+Troculeucel+Mechanism+Data+in+Alzheimer%E2%80%99s+and+Frontotemporal+Dementia+at+the+Neuroimmunology+Drug+Development+Summit/26292523.html Thu, 09 Apr 2026 08:05:00 -0400 A.17568957 A.50216539 NKGN O.01981133 O.04889877 O.50689666